狄建英


[摘要] 目的 探討應用欣母沛在高危剖宮產孕婦產后出血中的療效。方法 研究對象為方便選取2017年2月—2018年2月在該院接受剖宮產的80例高危孕婦,采取隨機數字表法將其分為對照組與研究組,每組40例。對照組給予縮宮素對孕婦產后出血進行預防,同時聯合應用卡孕栓直腸給藥。研究組給予欣母沛對孕婦產后出血進行預防,對兩組孕婦的產后出血量、術中術后輸血、宮紗條及球囊使用、術后子宮恢復等臨床指標進行對比分析。結果 產后出血量對比:研究組孕婦術中出血量為﹙102.33±19.98﹚mL、產后2 h出血量為﹙207.62±65.14﹚mL、產后24 h出血量為﹙40.45±32.64﹚mL;對照組孕婦術中出血量為﹙234.15±26.43﹚mL、產后2 h出血量為﹙321.09±80.42﹚mL、產后24 h出血量為﹙84.12±50.07﹚mL;研究組孕婦術中出血量、產后2 h出血量以及產后24 h出血量均顯著低于對照組(t=43.258、10.369、7.011,P=0.001、0.002、0.001)。研究組術中術后輸血、宮紗條使用、球囊使用、術后子宮恢復等各項臨床指標均明顯優于對照組(χ2=4.682、4.756、4.633、8.641,P=0.019、0.024、0.027、0.033)。結論 高危剖宮產孕婦應用欣母沛可對產后出血起到良好的防治作用,值得臨床加大研究并推廣采用。
[關鍵詞] 高危剖宮產;產后出血;欣母沛;防治療效
[中圖分類號] R714? ? ? ? ? [文獻標識碼] A? ? ? ? ? [文章編號] 1674-0742(2019)11(c)-0110-03
[Abstract] ObjectiveTo explore the efficacy of hemabate in the postpartum hemorrhage of high-risk cesarean section pregnant women.Methods The study subjects were 80 high-risk pregnant women who underwent cesarean section in our hospital from February 2017 to February 2018. They were convenient selection randomly divided into a control group and a study group, 40 cases each group. The control group was given oxytocin to prevent postpartum hemorrhage in pregnant women, and combined with rectal administration. The research group gave hemabate prevention of postpartum hemorrhage in pregnant women. The clinical indexes of postpartum hemorrhage, intraoperative blood transfusion, intrauterine strip and balloon use, and postoperative uterine recovery were compared. Results Comparison of postpartum hemorrhage: the intraoperative blood loss of the pregnant women in the study group was﹙102.33±19.98﹚mL, the bleeding volume at 20 h postpartum was﹙207.62±65.14﹚mL, and the bleeding volume at 24 h postpartum was ﹙40.45±32.64﹚mL. The intraoperative blood loss of the control group was ﹙234.15±26.43﹚mL, 2 h postpartum hemorrhage. The amount of blood was﹙32.1±09±80.42﹚mL, and the amount of bleeding was ﹙84.12±50.07﹚mLafter birth. The amount of intraoperative blood loss, postpartum hemorrhage and postpartum 24 bleeding in the study group were significantly lower than those in the control group(t=43.258, 10.369, 7.011, P=0.001, 0.002, 0.001). The blood transfusion and uterine strips were used in the study group. The clinical indexes of balloon use and postoperative uterine recovery were significantly better than the control group (χ2=4.682, 4.756, 4.633, 8.641, P=0.019, 0.024, 0.027, 0.033).ConclusionHigh-risk cesarean section pregnant women with hemabate can play a good role in prevention and treatment of postpartum hemorrhage, it is worthy of clinical research and promotion.
在鄧智華[8]的研究中,將200例高危剖宮產孕婦分為對比組與治療組進行研究,其中,對比組執行縮宮素預防手段,治療組執行欣母沛預防手段,結果顯示,治療組術中出血量(101.7±20.4)mL低于對比組(257.4±27.3)mL、產后2 h出血量(208.7±68.7)mL低于對比組(335.9±89.6)mL、產后24 h出血量(41.5±34.2)mL低于對比組(86.2±53.1)mL,差異有統計學意義(P<0.05)。臨床指標對比,治療組孕婦術中術后輸血量、宮紗條或球囊使用,術后子宮恢復良好比例均明顯優于對比組孕婦(P<0.05)。與該次研究結果高度一致,充分證實了此次研究的可信性。
綜上所述,該次研究再次論證了欣母沛藥物用于防治高危剖宮產孕婦產后出血的確切療效,利于促進產婦子宮修復,臨床應用前景可觀。
[參考文獻]
[1]? 高雅香. 欣母沛防治高危剖宮產孕婦產后出血臨床療效觀察[J]. 實用婦科內分泌雜志:電子版,2017,4(29):46,49.
[2]? 王彤,楊林,周煥弟. 欣母沛防治高危剖宮產孕婦產后出血的可行性分析[J]. 華夏醫學,2018,31(2):50-52.
[3]? 曾翠英. 欣母沛防治高危剖宮產孕婦產后出血的療效觀察[J]. 基層醫學論壇,2018,22(31):4396-4397.
[4]? Yaneth G R , Pieralessandro L , Hernández Fabián, et al. Cost-effectiveness of Carbetocin versus Oxytocin for Prevention of Postpartum Hemorrhage Resulting from Uterine Atony in Women at high-risk for bleeding in Colombia[J]. RevistaBrasileira de Ginecologia e Obstetrícia / RBGO Gynecology and Obstetrics, 2018, 40(5):242-250.
[5]? 楊燕嫣. 欣母沛防治高危剖宮產產婦產后出血的臨床效果分析[J]. 中外醫學研究,2016,14(16):112-113.
[6]? 吳敏. 欣母沛對于高危剖宮產孕婦產后出血的預防作用觀察與分析[J]. 中國醫藥指南,2017,15(13):145-146.
[7]? 楊亞莉, 馬穎, 郭永平. 欣母沛與米索前列醇片聯合治療頑固性宮縮乏力產后出血的臨床觀察[J]. 陜西醫學雜志, 2017, 46(4):527-528.
[8]? 鄧智華. 欣母沛防治高危剖宮產孕婦產后出血的療效觀察[J]. 中外女性健康研究,2018(6):76,78.
(收稿日期:2019-08-27)